TY - JOUR
T1 - Glucuronides
T2 - From biological waste to bio-nanomedical applications
AU - Burnouf, Pierre Alain
AU - Roffler, Steve R.
AU - Wu, Chia Ching
AU - Yu-Cheng, Su
N1 - Funding Information:
This study was supported by the Ministry of Science and Technology (MOST) of Taiwan (Grant 110-2314-B-006-118-MY2 ).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/9
Y1 - 2022/9
N2 - Long considered as no more than biological waste meant to be eliminated in urine, glucuronides have recently contributed to tremendous developments in the biomedical field, particularly against cancer. While glucuronide prodrugs monotherapy and antibody-directed enzyme prodrug therapy have been around for some time, new facets have emerged that combine the unique properties of glucuronides notably in the fields of antibody-drug conjugates and nanomedicine. In both cases, glucuronides are utilized as a vector to improve pharmacokinetics and confer localized activation of potent drugs at tumor sites while also decreasing systemic toxicity. Here we will discuss some of the most promising strategies using glucuronides to promote successful anti-tumor therapeutic treatments.
AB - Long considered as no more than biological waste meant to be eliminated in urine, glucuronides have recently contributed to tremendous developments in the biomedical field, particularly against cancer. While glucuronide prodrugs monotherapy and antibody-directed enzyme prodrug therapy have been around for some time, new facets have emerged that combine the unique properties of glucuronides notably in the fields of antibody-drug conjugates and nanomedicine. In both cases, glucuronides are utilized as a vector to improve pharmacokinetics and confer localized activation of potent drugs at tumor sites while also decreasing systemic toxicity. Here we will discuss some of the most promising strategies using glucuronides to promote successful anti-tumor therapeutic treatments.
UR - http://www.scopus.com/inward/record.url?scp=85135565025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135565025&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2022.07.031
DO - 10.1016/j.jconrel.2022.07.031
M3 - Review article
C2 - 35907593
AN - SCOPUS:85135565025
SN - 0168-3659
VL - 349
SP - 765
EP - 782
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -